Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sith Sathornsumetee

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Neuro-Oncology|March 13, 2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Bevacizumab plus irinotecan in recurrent glioblastoma multiformeJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Neuro-Oncology|March 25, 2008
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Neuro-Oncology|January 25, 2007
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins, Jennifer A Quinn, James J Vredenburgh, et al.
Cancer|August 10, 2005
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumorsJeremy N Rich, Sith Sathornsumetee, Stephen T Keir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon, Merrill J Egorin, Jennifer A Quinn, et al.
Acta Neuropathologica|December 30, 2021
Oligosarcomas, IDH-mutant are distinct and aggressiveAbigail K Suwala, Marius Felix, Dennis Friedel, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Neuro-Oncology|March 13, 2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Bevacizumab plus irinotecan in recurrent glioblastoma multiformeJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Neuro-Oncology|March 25, 2008
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Neuro-Oncology|January 25, 2007
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins, Jennifer A Quinn, James J Vredenburgh, et al.
Cancer|August 10, 2005
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumorsJeremy N Rich, Sith Sathornsumetee, Stephen T Keir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon, Merrill J Egorin, Jennifer A Quinn, et al.
Acta Neuropathologica|December 30, 2021
Oligosarcomas, IDH-mutant are distinct and aggressiveAbigail K Suwala, Marius Felix, Dennis Friedel, et al.
Pageof 6